Jim Pearce

Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.

Analyst Articles

During an “Investor Day” presentation to Wall Street analysts this morning in Manhattan, Argos Therapeutics (ARGS) confirmed that the critical ADAPT-3 trial for its AGS-003 cancer immunotherapy treatment is on schedule and appears headed for commercial use in the near future. The company announced two developments that suggest this… Read More

It’s hard to perform better than LeMaitre Vascular (LMAT) has been doing lately. In October it reported record sales and increased guidance for the remainder of the year, and last month it made an acquisition that is projected to be immediately accretive to both revenue and earnings. Although LeMaitre’s… Read More

Since adding The Buckle (BKE) to our portfolio on Nov. 10, its share price has appreciated more than 10% over our buy limit, even though its quarterly earnings report released one week later came in below expectations. The company reported third-quarter profits of 48 cents per share, three pennies shy… Read More

It’s too early for retail analysts to determine what type of holiday season this is going to be for Michael Kors (KORS), which primarily sells higher-priced women’s apparel. The company aggressively matched discounts offered by its rivals over the Black Friday weekend, calling into question the profitability of those sales… Read More

A couple of days after we added Cardinal Health (CAH) to our portfolio two weeks ago, the company announced it had entered into an agreement with Navidea Biopharmaceuticals to market its radioactive cancer diagnostic product throughout North America. The two companies had already been working together, splitting sales proceeds… Read More

According to conventional wisdom, Donald Trump’s victory was supposed to suppress gun sales for companies like Sturm, Ruger & Co. (RGR) because the odds of stricter gun control laws should be considerably diminished under an NRA-friendly administration. Sales of firearms were running high in the months leading up to the… Read More

Our most recent addition to the portfolio has only been open for a few days, so there isn’t much more to say about since last week’s alert. We bought USANA Health Sciences (USNA) a week after its stock split 2 for 1, and so far its share price continues… Read More

Until Nov. 8, the day of the U.S. presidential election, shares of Delphi Automotive (DLPH) were zooming up the charts after the company reported another solid set of quarterly numbers the week before. But Donald Trump’s unexpected victory sent DLPH tumbling on fears that possible trade wars with Mexico… Read More

We bought GNC Holdings (GNC) on Nov. 3 after its share price plunged 40% in late October on the heels of a disappointing quarterly earnings report that missed on both the top and bottom lines. We felt the selling that followed that news was excessive, setting the stage for a… Read More